Among 1990 patients with node-positive, hormone receptor-negative, or ERBB2-positive invasive breast cancer, 295 of 370 women (79.7%) with diabetes and 1464 of 1620 women (90.4%) without diabetes received chemotherapy. This evidence concerns the gene ERBB2 and invasive breast carcinoma.